Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
The in-vitro activity of a new glycopeptide antibiotic, LY333328, was compared with vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, vancomycin and teicoplanin resistant enterococci, and vancomycin sensitive and resistant enterococci. MIC, MBC, and time-kill kinetics were determined for each agent. LY333328 displayed similar or improved MIC/MBC values in comparison with vancomycin and teicoplanin. Time-kill kinetics for LY333328 demonstrated significantly improved bactericidal activity against the isolates. These findings suggest that LY333328 has improved in-vitro activity over vancomycin and teicoplanin against a range of gram-positive organisms.
Harland
S
S
Department of Microbiology, University Hospital Birmingham NHS Trust, Queen Elizabeth Hospital, Edgbaston, UK.
Tebbs
S E
SE
Elliott
T S
TS
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects; D006020:Glycopeptides; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D007700:Kinetics; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects; D017334:Teicoplanin / Q000494:pharmacology*; D013997:Time Factors; D014640:Vancomycin / Q000494:pharmacology* / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D017334:Teicoplanin; D014640:Vancomycin; C100708:oritavancin